<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37182548</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Trajectories of the evolution of post-COVID-19 condition, up to two years after symptoms onset.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>74</EndPage><MedlinePgn>67-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2023.05.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(23)00558-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We aimed to identify trajectories of the evolution of post-COVID-19 condition, up to 2 years after symptom onset.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The ComPaRe long COVID e-cohort is a prospective cohort of patients with symptoms lasting at least 2 months after SARS-CoV2 infection. We used trajectory modeling to identify different trajectories in the evolution of post-COVID-19 condition, based on symptoms collected every 60 days using the long COVID Symptom Tool.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 2197 patients were enrolled in the cohort between December 2020 and July 2022 when the Omicron variant was not dominant. Three trajectories of the evolution of post-COVID-19 condition were identified: "high persistent symptoms" (4%), "rapidly decreasing symptoms" (5%), and "slowly decreasing symptoms" (91%). Participants with highly persistent symptoms were older and more likely to report a history of systemic diseases. They often reported tachycardia, bradycardia, palpitations, and arrhythmia. Participants with rapidly decreasing symptoms were younger and more likely to report a confirmed infection. They often reported diarrhea and back pain. Participants with slowly decreasing symptoms were more likely to have a history of functional diseases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Most patients with post-COVID-19 condition improve slowly over time, while 5% have rapid improvement in the 2 years after symptom onset and 4% have a persistent condition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Servier</LastName><ForeName>Clemence</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, METHODS Team, CRESS, INSERM, INRA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porcher</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, METHODS Team, CRESS, INSERM, INRA, Paris, France; Assistance Publique-H&#xf4;pitaux de Paris, Centre d'&#xc9;pid&#xe9;miologie Clinique, H&#xf4;pital H&#xf4;tel-Dieu, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pane</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, METHODS Team, CRESS, INSERM, INRA, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravaud</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, METHODS Team, CRESS, INSERM, INRA, Paris, France; Assistance Publique-H&#xf4;pitaux de Paris, Centre d'&#xc9;pid&#xe9;miologie Clinique, H&#xf4;pital H&#xf4;tel-Dieu, Paris, France; Columbia University Mailman School of Public Health, Department of Epidemiology, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Viet-Thi</ForeName><Initials>VT</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, METHODS Team, CRESS, INSERM, INRA, Paris, France; Assistance Publique-H&#xf4;pitaux de Paris, Centre d'&#xc9;pid&#xe9;miologie Clinique, H&#xf4;pital H&#xf4;tel-Dieu, Paris, France. Electronic address: thi.tran-viet@aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Endotypes</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Natural history</Keyword><Keyword MajorTopicYN="N">Prospective cohort</Keyword><Keyword MajorTopicYN="N">Trajectory</Keyword></KeywordList><CoiStatement>Declarations of competing interest The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>14</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37182548</ArticleId><ArticleId IdType="pmc">PMC10176960</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2023.05.007</ArticleId><ArticleId IdType="pii">S1201-9712(23)00558-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . 2023. WHO Coronavirus Disease (COVID-19) Dashboard. [accessed 19 April 2023]</Citation><ArticleIdList><ArticleId IdType="pubmed">37068144</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics . 2021. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. [accessed 2 September 2021]</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Rodr&#xed;guez-Jim&#xe9;nez J, Cancela-Cilleruelo I, Guerrero-Peral A, Mart&#xed;n-Guerrero JD, Garc&#xed;a-Azor&#xed;n D, et al. Post-COVID-19 symptoms 2 years after SARS-CoV-2 infection among hospitalized vs nonhospitalized patients. JAMA Netw Open. 2022;5 doi: 10.1001/jamanetworkopen.2022.42106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.42106</ArticleId><ArticleId IdType="pmc">PMC9667330</ArticleId><ArticleId IdType="pubmed">36378309</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528. doi: 10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran VT, Porcher R, Pane I, Ravaud P. Course of post-COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 2022;13:1812. doi: 10.1038/s41467-022-29513-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29513-z</ArticleId><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400:452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747&#x2013;758. doi: 10.1016/S0140-6736(21)01755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6 doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Human Services. National research action plan on long covid., 2022.</Citation></Reference><Reference><Citation>Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open. 2021;4 doi: 10.1001/jamanetworkopen.2020.36142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.36142</ArticleId><ArticleId IdType="pmc">PMC7841464</ArticleId><ArticleId IdType="pubmed">33502487</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month Follow-up Chest CT findings after Severe COVID-19 Pneumonia. Radiology. 2021;299:E177&#x2013;E186. doi: 10.1148/radiol.2021203153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021203153</ArticleId><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333:575. doi: 10.1136/bmj.38933.585764.AE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of Covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort. BMJ Med. 2023;2 doi: 10.1136/bmjmed-2022-000229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000229</ArticleId><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Wang X, Lv T. Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon. J Med Virol. 2020;92:2286&#x2013;2287. doi: 10.1002/jmv.25952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25952</ArticleId><ArticleId IdType="pmc">PMC7267144</ArticleId><ArticleId IdType="pubmed">32347980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta J, Wiernik E, Robineau O, Carrat F, Touvier M, Severi G, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med. 2022;182:19&#x2013;25. doi: 10.1001/jamainternmed.2021.6454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6454</ArticleId><ArticleId IdType="pmc">PMC8576624</ArticleId><ArticleId IdType="pubmed">34747982</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I. CoviCare Study Team. Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting. Ann Intern Med. 2021;174:1252&#x2013;1260. doi: 10.7326/M21-0878.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-0878</ArticleId><ArticleId IdType="pmc">PMC8280535</ArticleId><ArticleId IdType="pubmed">34224254</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275&#x2013;1287. doi: 10.1016/S2213-2600(21)00383-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F, et al. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2021;174:723&#x2013;725. doi: 10.7326/M20-5926.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5926</ArticleId><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Schoot R, Sijbrandij M, Winter SD, Depaoli S, Vermunt JK. The GRoLTS-checklist: guidelines for reporting on latent trajectory studies. Struct Equ Model Multidiscip J. 2017;24:451&#x2013;467. doi: 10.1080/10705511.2016.1247646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10705511.2016.1247646</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran VT, Ravaud P. Collaborative Open platform E-cohorts for research acceleration in trials and epidemiology. J Clin Epidemiol. 2020;124:139&#x2013;148. doi: 10.1016/j.jclinepi.2020.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2020.04.021</ArticleId><ArticleId IdType="pubmed">32380177</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna BA, Lim EY, Mactavous L, NIHR BioResource Team. Lyons PA, Doffinger R, et al. Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. EBiomedicine. 2022;81 doi: 10.1016/j.ebiom.2022.104129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104129</ArticleId><ArticleId IdType="pmc">PMC9235296</ArticleId><ArticleId IdType="pubmed">35772216</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . 2022. WHO COVID-19 Case definition. [accessed 04 May 2023]</Citation></Reference><Reference><Citation>Tran VT, Riveros C, Clepier B, Desvarieux M, Collet C, Yordanov Y, et al. Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients' lived experience. Clin Infect Dis. 2021;74:278&#x2013;287. doi: 10.1093/cid/ciab352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371:m3731. doi: 10.1136/bmj.m3731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3731</ArticleId><ArticleId IdType="pmc">PMC7574532</ArticleId><ArticleId IdType="pubmed">33082154</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima C. 2022. Pre-normalizing a dependent variable using lcmm. [accessed 19 October 2022]</Citation></Reference><Reference><Citation>Institut National de la Statistique et des etudes &#xe9;conomiques . 2018. La Macro SAS CALMAR Inst Natl Stat Etudes Econ. [accessed 04 January 2019]</Citation></Reference><Reference><Citation>Proust-Lima C, Philipps V, Liquet B. Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: the R package lcmm. J Stat Soft. 2017;78:1&#x2013;56. doi: 10.18637/jss.v078.i02.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v078.i02</ArticleId></ArticleIdList></Reference><Reference><Citation>Sant&#xe9; Publique France . 2022. Suivi des variants pr&#xe9;occupants par s&#xe9;quen&#xe7;age. [accessed 19 December 2022]</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffieux H, Hanson AL, Lodge S, Lawler NG, Whiley L, Gray N, et al. A patient-centric characterization of systemic recovery from SARS-CoV-2 infection. Nat Immunol. 2023;24:349&#x2013;358. doi: 10.1038/s41590-022-01380-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01380-2</ArticleId><ArticleId IdType="pmc">PMC9892000</ArticleId><ArticleId IdType="pubmed">36717723</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28:911&#x2013;923. doi: 10.1038/s41591-022-01810-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert CR, Strahm C, G&#xfc;sewell S, Cusini A, Brucher A, Goppel S, et al. Post-acute sequelae after SARS-CoV-2 infection by viral variant and vaccination status: a multicenter cross-sectional study. Clin Infect Dis. 2023 doi: 10.1093/cid/ciad143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad143</ArticleId><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="pubmed">36905145</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>